Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
3.0
Journals
JPM
Special Issues
Integrative Multi-Omics for Novel Clinical Insights
share announcement

Integrative Multi-Omics for Novel Clinical Insights

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Omics/Informatics".

Deadline for manuscript submissions: closed (20 November 2020) | Viewed by 6591

Special Issue Editor

Dr. Brian Piening

E-Mail Website
Guest Editor
Earle A. Chiles Research Institute, Division of Providence Cancer Institute, 4805 NE Glisan St., Suite 2N88, Portland, OR 97213, USA
Interests: genomics; proteomics; bioinformatics; cancer; oncology

Special Issue Information

Dear colleagues,

Recent advances in high-throughput sequencing and other omics technologies have made it possible to generate a tremendous amount of biomolecular data on clinical cohorts. Moreover, it has been shown in a number of contexts that signatures combining multiple omics data types outperform single-analyte- or single-omic-based classifiers. Significant challenges remain, as the computational tools for integrating these diverse data types are still limited, and the interpretation of complex multi-omic datasets can be challenging.

This Special Issue will showcase novel basic, clinical, and in silico research that leverages the integration of multiple omics data types (e.g., genomics, proteomics, epigenomics, metabolomics, microbiomics, etc.) to elucidate the biology underlying clinical disease phenotypes (e.g. cancer, diabetes, neurological disease, etc.). Review articles surveying existing multi-omics research and methodology will also be featured.

Dr. Brian Piening
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • genomics
  • proteomics
  • metabolomics
  • microbiome
  • multi-omics
  • bioinformatics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

16 pages, 1574 KiB  
Review
Mass Spectrometry-Based Omics for the Characterization of Triple-Negative Breast Cancer Bio-Signature
by Ioana-Ecaterina Pralea, Radu-Cristian Moldovan, Adrian-Bogdan Țigu, Corina Ionescu and Cristina-Adela Iuga
J. Pers. Med. 2020, 10(4), 277; https://doi.org/10.3390/jpm10040277 - 12 Dec 2020
Cited by 12 | Viewed by 3954
Abstract
Triple-negative breast cancer (TNBC) represents an unmet medical need due to a high rate of metastatic occurrence and poor overall survival, pathology aggressiveness, heterogeneous clinical behavior and limited cytotoxic chemotherapy options available because of the absence of targetable receptors. The current standard of [...] Read more.
Triple-negative breast cancer (TNBC) represents an unmet medical need due to a high rate of metastatic occurrence and poor overall survival, pathology aggressiveness, heterogeneous clinical behavior and limited cytotoxic chemotherapy options available because of the absence of targetable receptors. The current standard of care in TNBC is represented by chemotherapy and surgery associated with low overall survival and high relapse rates. Hopes of overcoming current limited and unspecific approaches of TNBC therapy lie in studying the metabolic rewiring of these types of breast cancer, thus understanding the mechanisms involved in the occurrence and progression of the disease. Due to its heterogeneity, a clinically relevant sub-classification of this type of breast cancer based on biomarker panels is greatly needed in order to guide treatment decisions. Mass spectrometry-based omics may provide very useful tools to address the current needs of targetable biomarker discovery and validation. The present review aims to provide a comprehensive view of the current clinical diagnosis and therapy of TNBC highlighting the need for a new approach. Therefore, this paper offers a detailed mass spectrometry-based snapshot of TNBC metabolic adjustment, emphasizing a complex network of variables governing the diverse and aggressive clinical behavior of TNBC. Full article
(This article belongs to the Special Issue Integrative Multi-Omics for Novel Clinical Insights)
►▼ Show Figures

Figure 1

22 pages, 288 KiB  
Review
An Overview of the Application of Systems Biology in an Understanding of Chronic Rhinosinusitis (CRS) Development
by Michał Michalik, Alfred Samet, Agnieszka Dmowska-Koroblewska, Adrianna Podbielska-Kubera, Małgorzata Waszczuk-Jankowska, Wiktoria Struck-Lewicka and Michał J. Markuszewski
J. Pers. Med. 2020, 10(4), 245; https://doi.org/10.3390/jpm10040245 - 26 Nov 2020
Cited by 8 | Viewed by 2176
Abstract
Chronic rhinosinusitis (CRS) is an inflammatory disease of the paranasal sinuses. It is defined as the presence of a minimum of two out of four main symptoms such as hyposmia, facial pain, nasal blockage, and discharge, which last for 8–12 weeks. CRS significantly [...] Read more.
Chronic rhinosinusitis (CRS) is an inflammatory disease of the paranasal sinuses. It is defined as the presence of a minimum of two out of four main symptoms such as hyposmia, facial pain, nasal blockage, and discharge, which last for 8–12 weeks. CRS significantly impairs a patient’s quality of life. It needs special treatment mainly focusing on preventing local infection/inflammation with corticosteroid sprays or improving sinus drainage using nasal saline irrigation. When other treatments fail, endoscopic sinus surgery is considered an effective option. According to the state-of-the-art knowledge of CRS, there is more evidence suggesting that it is more of an inflammatory disease than an infectious one. This condition is also treated as a multifactorial inflammatory disorder as it may be triggered by various factors, such as bacterial or fungal infections, airborne irritants, defects in innate immunity, or the presence of concomitant diseases. Due to the incomplete understanding of the pathological processes of CRS, there is a continuous search for new indicators that are directly related to the pathogenesis of this disease—e.g., in the field of systems biology. The studies adopting systems biology search for possible factors responsible for the disease at genetic, transcriptomic, proteomic, and metabolomic levels. The analyses of the changes in the genome, transcriptome, proteome, and metabolome may reveal the dysfunctional pathways of inflammatory regulation and provide a clear insight into the pathogenesis of this disease. Therefore, in the present paper, we have summarized the state-of-the-art knowledge of the application of systems biology in the pathology and development of CRS. Full article
(This article belongs to the Special Issue Integrative Multi-Omics for Novel Clinical Insights)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop